Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia. We are primarily interested to examine the actions of Ginseng combined with antipsychotics in improving the ways patients diagnosed with schizophrenia behave in social environment, store, process and retrieve information.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Collaborators: Imperial College London; Northern Ontario School of Medicine; Queen's University
• Treatments: Antipsychotic Agents

Criteria

Inclusion Criteria:

• Male or female

• age 18-65 years

• DSM-IV diagnosis of Schizophrenia

• SANS score greater than 30

Exclusion Criteria:

• Current (past 12 months) substance use disorder

• Except nicotine dependence

• Major medical disorders : hematological disorder

• Chronic active hepatitis, acute hepatitis, cirrhosis of liver, AIDS

• Pregnancy and breast-feeding

• Neurological disorders including epilepsy

• traumatic brain injury

• HAM-D score greater than 24